AIM Bull's-Eye Award for Innovation and Excellence in Immunization
2024 Nomination Process

BULL’S-EYE AWARD

The AIM Bull's-Eye Award for Innovation and Excellence in Immunization is presented to state, territorial, or local immunization programs (National Center for Immunization and Respiratory Diseases (NCIRD) awardees) in recognition of outstanding immunization initiatives. Only submissions received from one of the 64 city, state, or territorial immunization programs directly funded by the Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases [The 50 states, the District of Columbia, American Samoa, Guam, the Republic of Marshall Islands, Micronesia, the Northern Mariana Islands, Palau, Puerto Rico, the Virgin Islands, Chicago, New York City, Houston, San Antonio, Philadelphia] will be considered.

The award recognizes immunization strategies that "hit their mark," achieving goals and increasing awareness by encouraging replication in other programs. **Only those initiatives that are currently ongoing or those that concluded January 2022 through the present are eligible for the Bull's-Eye Award.** Three Bull's-Eye Awards will be selected and will be presented at the AIM Leadership in Action Conference (December 2024, New Orleans, LA). The three programs awarded with the Bull's-Eye will be notified in advance and will be invited to give a short presentation to the AIM membership at the 2024 Leadership in Action Conference.

**PLEASE NOTE:** The 64 federal immunization awardees are eligible to nominate themselves or others for a Bull's-Eye Award; all nominations must be NCIRD awardees. Programs may submit multiple initiatives; however, each program may only submit a maximum of THREE initiatives for consideration for the 2024 Bull's Eye Award.

SUBMISSION PROCESS FOR BULL’S-EYE AWARD

- All nominations must be submitted using the AIM Program Practices form.
- Each submission cannot exceed 3 pages.
- Each of the Submission Components on the submission form must be addressed.
- Only those initiatives that are currently ongoing or those that concluded January 2022 through the present are eligible for the Bull's-Eye Award.
- Submissions must demonstrate effectiveness of the initiative (either with evaluation data, including preliminary results, or by showing other means of assessing and interpreting effectiveness, such as observations or estimations).
All submissions (regardless of whether they are selected as Bull's-Eye winners) will be entered into the publicly accessible AIM Program Practices database.

**SUBMISSION LENGTH**

Brevity is key! The intent and expectation are not for programs to write a lengthy description about the activity, but rather to provide a brief "snapshot" of the activity. Utilizing the submission form, please keep submissions to 3 pages or less.

**SUBMISSION COMPONENTS**

Please see the [2024 Program Practices Submission Process](#) document for more information on the submission components.

**REVIEW PROCESS FOR BULL’S EYE AWARD**

The Submission Components (listed below) on the AIM Bull's-Eye submission form will be scored as follows:

- **Background:** 5 points
- **Description:** 5 points
- **Effectiveness:** 20 points
- **Conclusions / Lessons learned:** 10 points
- **Potential for replication:** 20 points
- **Innovation:** 40 points

**DUE DATES**

To be considered for the 2024 Bull's-Eye Award, submissions must be received by **11:59 pm EST on Monday, September 9, 2024**. Please email submissions to Mikaela Mendoza Pereira at [mpereira@immunizationmanagers.org](mailto:mpereira@immunizationmanagers.org) and include "Bull's-Eye Submission" in the subject line.

**NOTIFICATION**

All those submitting for the Bull's-Eye Award will be notified of their status in October 2024. The three programs awarded with the Bull's-Eye will be invited to give a short presentation to the AIM membership at the Leadership in Action Conference in New Orleans, LA, in December 2024.

**QUESTIONS**

Please direct any questions about the Bull’s-Eye Award submission process to Mikaela Mendoza Pereira at [mpereira@immunizationmanagers.org](mailto:mpereira@immunizationmanagers.org).